Treatment
Low molecular weight heparin clinical trials
We’re tracking 12 recruiting studies that include Low molecular weight heparin, each written for real people, not researchers, below.
Recruiting studies
- NCT06575309Recruiting
Blood clotting in pregnancy and the effect of blood thinner
This study looks at how blood clotting changes during pregnancy and how a common blood thinner affects clotting in the lab. It may help doctors understand pregnancy-related clotting risks better.
Clermont-FerrandAges 18–55 - NCT06355258RecruitingPhase 1
Troxerutin to prevent blood clots in COVID-19 patients
This trial tests if the drug troxerutin can prevent dangerous blood clots in adults hospitalized with mild or severe COVID-19. If you have COVID-19 and are not already on blood thinners or at high risk for bleeding, you may be able to join.
Shaoxing, ZhejiangAges 18 years+ - NCT04861103RecruitingPhase 4
Testing a blood thinner plan during pregnancy
This study looks at how people’s blood and clotting behave during pregnancy when taking a specific blood thinner called low molecular weight heparin (LMWH) three times a day. It may help doctors fine-tune how safely and effectively LMWH is used during pregnancy.
Orange, CaliforniaAges 18 years+ - NCT06494878RecruitingPhase 3
Aspirin after childbirth to prevent blood clots
This trial tests if taking aspirin after delivery helps prevent dangerous blood clots in women with certain risk factors. It's for new mothers who have a clotting disorder, were on bed rest, or have multiple other risk factors like high weight or preeclampsia.
BrusselsAges 18 years+ - NCT07140211RecruitingPhase 3
Low-dose heparin to prevent blood clots after childbirth
This trial is testing a short course of a low-dose blood thinner (heparin) to prevent dangerous blood clots in the legs or lungs after childbirth. It is for women who have certain risk factors that make clots more likely.
BadenAges 18 years+ - NCT04918524Recruiting
Pregnancy outcomes in women with certain autoimmune conditions
This study looks at the typical pregnancy course and outcomes for women with APS or UCTD, two autoimmune-related conditions. It also checks how these conditions and treatments may affect pregnancy, so doctors can better plan care.
Jinan, ShandongAges 20–45 - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
La Jolla, CaliforniaAges 18 years+ - NCT05634057Recruiting
Treating sepsis with a medication plus blood thinner
This trial studies whether combining anisodamine (a medicine for certain gut/smooth-muscle effects) with a low-molecular-weight blood thinner helps treat sepsis. It may be aimed at improving outcomes compared with standard care, but eligibility depends on safety factors like bleeding risk and organ function.
Beijing, ChinaAges 18–110 - NCT06195540RecruitingPhase 3
Rivaroxaban versus LMWH for leg injuries needing a cast
This trial compares two blood thinners (rivaroxaban pills versus LMWH shots) to see which is better at preventing blood clots in people with leg injuries that require a cast or brace. If you qualify, you can receive one of these treatments while your leg heals.
AgenAges 18 years+ - NCT06753786Recruiting
Blood thinner timing study for bleeding stroke patients
This study looks at when it is safest to start blood thinners to prevent blood clots (deep vein thrombosis) after a type of bleeding stroke called hypertensive intracerebral hemorrhage. Researchers want to find the best time to start this prevention treatment.
MoscowAges 18 years+ - NCT06845423RecruitingPhase 4
Preventing blood clots after childbirth in women at intermediate risk
This study tests whether giving a short course of a daily blood-thinning injection (enoxaparin) after childbirth can safely prevent blood clots in women at intermediate risk. If you qualify, you would receive the injection or a placebo (inactive shot) for up to 5 days while in the hospital.
AmiensAges 18 years+ - NCT07270263Recruiting
Lower-dose blood thinners for people with blood cancers
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
Gdansk, Pomeranian VoivodeshipAges 18 years+
What Low molecular weight heparin is being studied for
Conditions with recruiting Low molecular weight heparin studies.
Common questions
- Are there clinical trials studying Low molecular weight heparin?
- Yes. Clin2 currently lists 12 recruiting studies that include Low molecular weight heparin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Low molecular weight heparin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Low molecular weight heparin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Low molecular weight heparin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.